CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Bookmark and Share
Published: 9 Jun 2021
Views: 357
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

Dr Jedd Wolchok speaks to ecancer about the six-and-a-half-year outcomes of CheckMate067 trial.

Initially, he explains the background of the trial. CheckMate -067 is a randomised, double-blind, phase 3 clinical trial, demonstrating durable improvement in survival with first-line nivolumab plus ipilimumab therapy and nivolumab monotherapy, versus ipilimumab alone, in patients with advanced melanoma.

Dr Wolchok then discusses the methodology and key results of this study that were presented at ASCO 2021. The safety profile for nivolumab plus ipilimumab was consistent with prior findings, with no new safety signals observed and no additional treatment-related deaths occurring since the five-year analysis. Grade 3/4 treatment-related adverse events were reported in 59% of patients in the combination group, 24% of patients in the nivolumab group, and 28% of patients in the ipilimumab group.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.